On Monday, shares of Akamai Technologies, Inc. (NASDAQ:AKAM), included 0.69% and shut at $66.90 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $66.05 and $67.10. Akamai Technologies, Inc. (AKAM), the global leader in Content Delivery Network (CDN) services, recently released plans for the building of its new global headquarters in Cambridge, Massachusetts. Akamai has reached a contract with Boston Properties to lease a newly-constructed building at 145 Broadway, in the heart of Cambridge’s Kendall Square neighborhood. The about 486,000 square foot building is planned to open at the end of 2019.
“Akamai has its roots in Cambridge and has grown into the leading technology company headquartered in this area,” said Erica Chapman, Vice President, Global Real Estate and Workplace Productivity at Akamai. “We look forward to creating a campus environment for Akamai’s employees to further foster innovation and collaboration, and to build a headquarters that complements the thriving Kendall Square community, complete with first-floor retail space.”
Shares of StemCells Inc (NASDAQ:STEM), subtract -2.29% and shut at $1.28 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $1.20 and $1.37. The association’s commercial center capitalization is $24.56 Billion with the general uncommon loads of 16.26 million. StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and related technologies. It develops HuCNS-SC platform technology, a purified human neural stem cells used as a potential therapeutic to treat diseases and disorders of the central nervous system. The companys HuCNS-SC is in Phase I clinical trials for the treatment of Pelizeaus-Merzbacher Disease; and has accomplished a Phase I clinical trial for infantile and late infantile neuronal ceroid lipofuscinosis.